{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:04:39Z","timestamp":1776801879440,"version":"3.51.2"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.7759\/cureus.107486","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:53:56Z","timestamp":1776797636000},"source":"Crossref","is-referenced-by-count":0,"title":["Silent Aggressor: Unveiling Large-Cell Duodenal Neuroendocrine Carcinoma"],"prefix":"10.7759","author":[{"given":"Shyamal","family":"Sheth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shil","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilemahos","family":"Spyratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000335595","article-title":"ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave G","year":"2012","unstructured":"Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al.. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012, 95:74-87. 10.1159\/000335595","journal-title":"Neuroendocrinology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072006","article-title":"Surgical management of pancreatic neuroendocrine tumors","volume":"15","author":"Sulciner ML","year":"2023","unstructured":"Sulciner ML, Clancy TE. Surgical management of pancreatic neuroendocrine tumors. Cancers (Basel). 2023, 15:10.3390\/cancers15072006","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.120","article-title":"Neuroendocrine neoplasms of the gut and pancreas: new insights","volume":"8","author":"Rindi G","year":"2011","unstructured":"Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011, 8:54-64. 10.1038\/nrendo.2011.120","journal-title":"Nat Rev Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye H","year":"2014","unstructured":"Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014, 120:2814-23. 10.1002\/cncr.28721","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao JC","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al.. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26:3063-72. 10.1200\/JCO.2007.15.4377","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal ID","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al.. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020, 76:182-8. 10.1111\/his.13975","journal-title":"Histopathology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000443168","article-title":"ENETS Consensus Guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Delle Fave G","year":"2016","unstructured":"Delle Fave G, O'Toole D, Sundin A, et al.. ENETS Consensus Guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016, 103:119-24. 10.1159\/000443168","journal-title":"Neuroendocrinology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard SC","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011, 364:1844-54. 10.1056\/NEJMra0904569","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo MS","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Brit J Haematol. 2004, 127:3-11.","journal-title":"Brit J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye H","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, et al.. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013, 24:152-60. 10.1093\/annonc\/mds276","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000443172","article-title":"ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero R","year":"2016","unstructured":"Garcia-Carbonero R, Sorbye H, Baudin E, et al.. ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016, 103:186-94. 10.1159\/000443172","journal-title":"Neuroendocrinology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009074","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","volume":"12","author":"Patel SP","year":"2024","unstructured":"Patel SP, Othus M, Chae YK, et al.. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort. J Immunother Cancer. 2024, 12:10.1136\/jitc-2024-009074","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335306-silent-aggressor-unveiling-large-cell-duodenal-neuroendocrine-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:53:56Z","timestamp":1776797636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335306-silent-aggressor-unveiling-large-cell-duodenal-neuroendocrine-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.107486","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}